Preliminary evidence of HIV seroconversion among HIV-negative men who have sex with men taking non-prescribed antiretroviral medication for HIV prevention in Miami, Florida, USA
Preliminary evidence of HIV seroconversion among HIV-negative men who have sex with men taking non-prescribed antiretroviral medication for HIV prevention in Miami, Florida, USA
复制标题
DOI：
10.1071/sh16108
复制
发表时间：
2017-01-01
期刊：
影响因子：
1.6
通讯作者：
Kurtz, Steven P.
中科院分区：
文献类型：
--
作者：
Buttram, Mance E.;Kurtz, Steven P.
背景资料：有限的信息表明，男男性行为者（MSM）正在非正式地获得抗逆转录病毒药物（ARV），并将其用于艾滋病毒暴露前预防（PrEP）。研究方法：数据来自一项正在进行的研究，研究使用非处方抗逆转录病毒药物的PrEP。迄今为止，24定性访谈已进行了艾滋病毒阴性，物质使用的男男性接触者生活在迈阿密，佛罗里达，美国。数据来自两名参与者，他们报告在使用非处方抗逆转录病毒药物进行PrEP. Results时发生了HIV血清转换：初步数据表明，一些年轻的MSM：（i）缺乏对PrEP有效使用的认识和准确信息;（ii）从爱滋病病毒感染者取得非处方抗逆转录病毒药物─积极的性伴侣，并使用这些药物的PrEP的方式，不提供足够的保护，防止艾滋病毒感染或与（iii）从事多种艾滋病毒传播风险行为，包括无安全套肛交和注射毒品。结论：非正式、未经批准和未经医疗监督的使用抗逆转录病毒药物预防艾滋病毒有可能破坏PrEP的保护作用，使男性无法预防艾滋病毒传播，并面临抗逆转录病毒药物耐药性的风险。
Background: Limited information suggests that men who have sex with men (MSM) are informally obtaining antiretroviral medication (ARVs) and using them for HIV pre-exposure prophylaxis (PrEP). Methods: Data are drawn from an on-going study examining the use of non-prescribed ARVs for PrEP. To date, 24 qualitative interviews have been conducted with HIV-negative, substance-using MSM living in Miami, Florida, USA. Data are presented from two participants who reported HIV seroconversion while using non-prescribed ARVs for PrEP. Results: Preliminary data indicate that some young MSM: (i) lack awareness of and accurate information about the efficacious use of PrEP; (ii) obtain non-prescribed ARVs from HIV-positive sex partners and use these medications for PrEP in a way that does not provide adequate protection against HIV infection or cohere with established guidelines; and (iii) engage in multiple HIV transmission risk behaviours, including condomless anal sex and injection drug use. Conclusions: The informal, non-rescribed and non-medically supervised use of ARVs for HIV prevention has the potential to undermine the protective benefits of PrEP and leave men unprotected against HIV transmission and at risk for ARV resistance.